CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience
Abstract Background Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected patients with migraine and chronic daily headache without any headache fr...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | https://doi.org/10.1186/s10194-021-01323-6 |
id |
doaj-b731ecb7817c491b94df4ef044ea44d5 |
---|---|
record_format |
Article |
spelling |
doaj-b731ecb7817c491b94df4ef044ea44d52021-09-26T11:48:43ZengBMCThe Journal of Headache and Pain1129-23691129-23772021-09-012211610.1186/s10194-021-01323-6CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experienceArmin Scheffler0Hannah Schenk1Sebastian Wurthmann2Michael Nsaka3Christoph Kleinschnitz4Martin Glas5Dagny Holle6Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-EssenDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-EssenDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-EssenDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-EssenDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-EssenDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Hospital Essen, University Duisburg-EssenDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-EssenAbstract Background Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected patients with migraine and chronic daily headache without any headache free days were excluded. Thus, less is known about the effectiveness of CGRP antibody treatment in this cohort. Methods Clinical routine data of 32 patients with migraine and daily headache were analysed after three months of treatment with a CGRP antibody (16 erenumab, 7 galcanezumab, 9 fremanezumab), including changes of monthly headache days (MHD) monthly migraine days (MMD) and monthly acute medication intake (AMD) as well as migraine characteristics. Statistical analysis was performed with the Wilcoxon-Test. Migraine characteristics were analysed descriptively. Results The number of MHD was significantly reduced (mean reduction (standard error), p-value): (-4.2 (1.3), p = 0.009) as well as MMD (-4.3 (1.6), p = 0.033). Four patients (13 %) reached a 50 % reduction regarding MHD and 8 patients (25 %) regarding MMD, migraine duration and intensity improved under therapy. Conclusions Despite the low responder rate, CGRP antibodies can be effective at least in a few cases of severely affected patients with drug resistant migraine and chronic daily headache. Trial registration Retrospective registered.https://doi.org/10.1186/s10194-021-01323-6MigraineCGRP antibodyTherapyReal-worldChronic daily headache |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Armin Scheffler Hannah Schenk Sebastian Wurthmann Michael Nsaka Christoph Kleinschnitz Martin Glas Dagny Holle |
spellingShingle |
Armin Scheffler Hannah Schenk Sebastian Wurthmann Michael Nsaka Christoph Kleinschnitz Martin Glas Dagny Holle CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience The Journal of Headache and Pain Migraine CGRP antibody Therapy Real-world Chronic daily headache |
author_facet |
Armin Scheffler Hannah Schenk Sebastian Wurthmann Michael Nsaka Christoph Kleinschnitz Martin Glas Dagny Holle |
author_sort |
Armin Scheffler |
title |
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience |
title_short |
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience |
title_full |
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience |
title_fullStr |
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience |
title_full_unstemmed |
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience |
title_sort |
cgrp antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience |
publisher |
BMC |
series |
The Journal of Headache and Pain |
issn |
1129-2369 1129-2377 |
publishDate |
2021-09-01 |
description |
Abstract Background Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected patients with migraine and chronic daily headache without any headache free days were excluded. Thus, less is known about the effectiveness of CGRP antibody treatment in this cohort. Methods Clinical routine data of 32 patients with migraine and daily headache were analysed after three months of treatment with a CGRP antibody (16 erenumab, 7 galcanezumab, 9 fremanezumab), including changes of monthly headache days (MHD) monthly migraine days (MMD) and monthly acute medication intake (AMD) as well as migraine characteristics. Statistical analysis was performed with the Wilcoxon-Test. Migraine characteristics were analysed descriptively. Results The number of MHD was significantly reduced (mean reduction (standard error), p-value): (-4.2 (1.3), p = 0.009) as well as MMD (-4.3 (1.6), p = 0.033). Four patients (13 %) reached a 50 % reduction regarding MHD and 8 patients (25 %) regarding MMD, migraine duration and intensity improved under therapy. Conclusions Despite the low responder rate, CGRP antibodies can be effective at least in a few cases of severely affected patients with drug resistant migraine and chronic daily headache. Trial registration Retrospective registered. |
topic |
Migraine CGRP antibody Therapy Real-world Chronic daily headache |
url |
https://doi.org/10.1186/s10194-021-01323-6 |
work_keys_str_mv |
AT arminscheffler cgrpantibodytherapyinpatientswithdrugresistantmigraineandchronicdailyheadachearealworldexperience AT hannahschenk cgrpantibodytherapyinpatientswithdrugresistantmigraineandchronicdailyheadachearealworldexperience AT sebastianwurthmann cgrpantibodytherapyinpatientswithdrugresistantmigraineandchronicdailyheadachearealworldexperience AT michaelnsaka cgrpantibodytherapyinpatientswithdrugresistantmigraineandchronicdailyheadachearealworldexperience AT christophkleinschnitz cgrpantibodytherapyinpatientswithdrugresistantmigraineandchronicdailyheadachearealworldexperience AT martinglas cgrpantibodytherapyinpatientswithdrugresistantmigraineandchronicdailyheadachearealworldexperience AT dagnyholle cgrpantibodytherapyinpatientswithdrugresistantmigraineandchronicdailyheadachearealworldexperience |
_version_ |
1716867728799694848 |